☆ 4.6 Editorial Material

Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?

JOURNAL OF CROHNS & COLITIS (2016)

期刊

JOURNAL OF CROHNS & COLITIS

卷 10, 期 11, 页码 1257-1258

出版社

OXFORD UNIV PRESS

DOI: 10.1093/ecco-jcc/jjw119

关键词

-

类别

Gastroenterology & Hepatology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Medicine, General & Internal

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops, James L. Izanec, Long-Long Gao, Christopher Gasink, Andrew Greenspan, Matthieu Allez, Silvio Danese, Stephen B. Hanauer, Vipul Jairath, Tanja Kuehbacher, James D. Lewis, Edward V. Loftus, Emese Mihaly, Remo Panaccione, Ellen Scherl, Oksana B. Shchukina, William J. Sandborn

Summary: This study evaluated the efficacy and safety of monotherapy with ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease. The results showed that both drugs were highly effective with no significant difference in the primary outcome.

LANCET (2022)

添加到收藏夹

Article Medicine, Research & Experimental

A potential pathogenic association between periodontal disease and Crohn's disease

Jin Imai, Hitoshi Ichikawa, Sho Kitamoto, Jonathan L. Golob, Motoki Kaneko, Junko Nagata, Miho Takahashi, Merritt G. Gillilland, Rika Tanaka, Hiroko Nagao-Kitamoto, Atsushi Hayashi, Kohei Sugihara, Shrinivas Bishu, Shingo Tsuda, Hiroyuki Ito, Seiichiro Kojima, Kazunari Karakida, Masashi Matsushima, Takayoshi Suzuki, Katsuto Hozumi, Norihito Watanabe, William Giannobile, Takayuki Shirai, Hidekazu Suzuki, Nobuhiko Kamada

Summary: The study found that in patients with ulcerative colitis (UC) and Crohn's disease (CD), the gut microbiome was more similar to the oral microbiome, indicating increased ectopic gut colonization by oral bacteria in IBD patients. Incipient periodontitis did not significantly affect the clinical outcomes of UC and CD patients, but early periodontitis may be associated with worse clinical symptoms in some CD patients.

JCI INSIGHT (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays

Rachel Nice, Neil Chanchlani, Harry Green, Claire Bewshea, Tariq Ahmad, James R. Goodhand, Timothy J. McDonald, Mandy H. Perry, Nicholas A. Kennedy

Summary: This study validates the positivity thresholds for drug-tolerant anti-infliximab and -adalimumab antibody assays, and finds that low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure, particularly for adalimumab. It highlights the importance of deriving antibody positivity thresholds for accurate detection and treatment outcomes.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches

Hicham Wahnou, Ibtissam Youlyouz-Marfak, Bertrand Liagre, Vincent Sol, Mounia Oudghiri, Raphael Emmanuel Duval, Youness Limami

Summary: Prostate cancer is a major concern worldwide, and current treatments have limitations and side effects. Photodynamic therapy (PDT) is a promising alternative that uses light-activated photosensitizers to induce tumor cell death. There are synthetic and natural photosensitizers, and combining PDT with other therapies is being explored. This review provides an overview of conventional treatments, principles of PDT, different types of photosensitizers, and ongoing research on combination therapy for prostate cancer. PDT has the potential to be a more effective and less invasive treatment option, and research aims to improve its selectivity and efficacy.

PHARMACEUTICS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial

Reinier C. A. van Linschoten, Fenna M. Jansen, Renske W. M. Pauwels, Lisa J. T. Smits, Femke Atsma, Wietske Kievit, Dirk J. de Jong, Annemarie C. de Vries, Paul J. Boekema, Rachel L. West, Alexander G. L. Bodelier, Ingrid A. M. Gisbertz, Frank H. J. Wolfhagen, Tessa E. H. Romkens, Maurice W. M. D. Lutgens, Adriaan A. van Bodegraven, Bas Oldenburg, Marieke J. Pierik, Maurice G. V. M. Russel, Nanne K. de Boer, Rosalie C. Mallant-Hent, Pieter C. J. ter Borg, Andrea E. van der Meulen-de Jong, Jeroen M. Jansen, Sita Jansen, Adrianus C. I. T. L. Tan, C. Janneke van der Woude, Frank Hoentjen

Summary: The study aimed to assess the clinical outcomes of increased adalimumab dose intervals versus conventional dosing in patients with stable remission of Crohn's disease. The results showed that increasing the adalimumab dose intervals to 3 weeks and further to 4 weeks was non-inferior for maintaining stable remission, and this approach reduced the risk of infections and healthcare costs.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

IgA nephropathy in a child: Crohn's disease-associated or adalimumab induced?

Francesco Graziano, Martina Buse, Nicola Cassata, Vincenzo Luca Lentini, Michele Citrano

Summary: In pediatric patients with inflammatory bowel disease, IgA Nephropathy is a rare complication that can arise during treatment with anti-INF-alpha therapy. This case report describes an 11-year-old child who developed IgA Nephropathy 2 years after being diagnosed with Crohn disease and receiving anti-INF-alpha therapy, which was successfully managed with steroids and ACE inhibitors. Monitoring renal function, proteinuria, and autoantibodies is recommended for patients receiving anti-INF-alpha agents.

CURRENT MEDICAL RESEARCH AND OPINION (2022)

添加到收藏夹

Article Multidisciplinary Sciences

A combination of circulating microRNA-375-3p and chemokines CCL11, CXCL12, and G-CSF differentiate Crohn's disease and intestinal tuberculosis

Susree Roy, Suchandrima Ghosh, Mallica Banerjee, Sayantan Laha, Dipanjan Bhattacharjee, Rajib Sarkar, Sujay Ray, Arko Banerjee, Ranajoy Ghosh, Aniket Halder, Alakendu Ghosh, Raghunath Chatterjee, Simanti Datta, Gopal Krishna Dhali, Soma Banerjee

Summary: This study identified potential biomarkers for differentiating between intestinal tuberculosis (ITB) and Crohn's disease (CD) through analyzing miRNA and chemokines in patients. The combination of miR-375-3p + Eotaxin-1/CCL11 + SDF-1 alpha/CXCL12 + G-CSF showed better performance in distinguishing ITB from CD compared to single markers, with high specificity and positive predictive value.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Nutrition & Dietetics

Effectiveness of Crohn's Disease Exclusion Diet for Induction of Remission in Crohn's Disease Adult Patients

Martyna Szczubelek, Karolina Pomorska, Monika Korolczyk-Kowalczyk, Konrad Lewandowski, Magdalena Kaniewska, Grazyna Rydzewska

Summary: Exclusive enteral nutrition (EEN) and Crohn's disease exclusion diet (CDED) are both effective in inducing remission in pediatric CD patients. The study demonstrates that CDED is equally effective in adult CD patients, with 76.7% achieving clinical remission after 6 weeks.

NUTRIENTS (2021)

添加到收藏夹

Article Medicine, General & Internal

Azathioprine-induced toxoplasma gondii infection in a patient with Crohn's disease with NUDT15 variation A case report

Yanan Wu, Yuyong Tan, Dalian Ou, Xuehong Wang, Yongjun Wang

Summary: This case report highlights a Crohn's disease patient who developed toxoplasma gondii infection after treatment with azathioprine, with a genetic variation in NUDT15 but normal TPMP gene. NUDT15 variation may contribute to reduced tolerance to azathioprine and personalized therapy based on genetic testing may help reduce the risk of adverse events.

MEDICINE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials

Evelien M. J. Beelen, Daan Nieboer, Jeanine H. C. Arkenbosch, Miguel D. Regueiro, Jack Satsangi, Sandro Ardizzone, Antonio Lopez-Sanroman, Edoardo Savarino, Alessandro Armuzzi, C. Janneke van der Woude, Annemarie C. de Vries

Summary: This meta-analysis found that anti-TNF-alpha treatment is superior to thiopurine prophylaxis for preventing endoscopic and clinical recurrence of Crohn's disease after ileocolonic resection. This advantage was confirmed in subgroup analysis and after risk stratification.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Relapsing autoimmune inner ear disease with significant response to methotrexate and azathioprine combination therapy: A case report and mini literature review

Kuan-Hsuan Huang, Hsiao-Ching Lin, Chia-Der Lin, Po-Chang Wu

Summary: Autoimmune inner ear disease typically presents with progressive bilateral hearing loss that may not respond well to corticosteroid monotherapy. This case report highlights the successful use of a combination therapy of methylprednisolone, azathioprine, and methotrexate in a patient with autoimmune inner ear disease who had temporary response to corticosteroid monotherapy and multiple relapses. The combination therapy resulted in improved hearing and well-tolerated maintenance therapy.

MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)

Abhinav Vasudevan, Danny Con, Peter De Cruz, Miles P. Sparrow, Antony B. Friedman, Mayur Garg, Soleiman Kashkooli, Peter R. Gibson, Daniel R. van Langenberg

Summary: This study compared the use of thiopurine-allopurinol combination therapy with standard thiopurine therapy in IBD. The results showed that the thiopurine-allopurinol group had better outcomes in the primary efficacy assessment, fewer adverse events, and less frequent thiopurine dose adjustments.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Medicine, General & Internal

Crohn's Disease Exclusion Diet for the Treatment of Crohn's Disease: Real-World Experience from a Tertiary Center

Naomi Fliss-Isakov, Nathaniel Aviv Cohen, Ahuva Bromberg, Gal Elbert, Ronit Anbar, Yulia Ron, Ayal Hirsch, Tamar Thurm, Nitsan Maharshak

Summary: In this retrospective cohort study, the Crohn's Disease exclusion diet (CDED) was found to induce remission in pediatric and adult patients with CD. The study analyzed the real-world experience of using CDED at the inflammatory bowel disease unit of Tel Aviv Medical Center. The results showed that high adherence to CDED was associated with clinical remission at week 12.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Effect of Thiopurine on Potential Surgical Intervention in Crohn's Disease in Korea: Results from the CONNECT Study

Hee Man Kim, Jin Woo Kim, Hyun-Soo Kim, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Won Ho Kim, Byong Duk Ye, Won Moon, Sung Hee Jung, Young-Ho Kim, Dong Soo Han

Summary: This study in Korean patients with Crohn's disease found a significant association between the use of azathioprine/6-MP and TNF-alpha antagonists and a reduced risk of abdominal and perianal surgery.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Pediatrics

Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN

Tereza Lerchova, Ondrej Hradsky, Michal Kulich, Gabor Veres, Jorge Amil Dias, Malgorzata Sladek, Sanja Kolacek, Stephanie Van Biervliet, Jan Melek, Daniela E. Serban, Katrine Winther, Tim de Meij, Jan Schwarz, Kaija-Leena Kolho, Johanna C. Escher, Jiri Bronsky

Summary: This study developed a predictive model based on six baseline parameters to potentially predict early azathioprine treatment failure in pediatric CD patients. A web-based tool has been created to estimate individual relapse risk in pediatric CD patients on a particular therapeutic regimen.

PEDIATRIC RESEARCH (2023)

添加到收藏夹

Review Medicine, General & Internal

Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question

Roberto Gabbiadini, Ferdinando D'Amico, Alessandro De Marco, Maria Terrin, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Gionata Fiorino, Silvio Danese

Summary: Patients with ulcerative colitis and Crohn's disease in the colon are at higher risk of colorectal cancer (CRC). Surveillance colonoscopy is recommended as it can detect early-stage CRC. Dye chromoendoscopy (DCE) has been considered the most effective technique for detecting dysplasia, but advancements in endoscopic technology like high-definition colonoscopes and dye-less virtual chromoendoscopy (VCE) could alter future practices.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Review Medicine, General & Internal

Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases

Tommaso Lorenzo Parigi, Elisabetta Mastrorocco, Leonardo Da Rio, Mariangela Allocca, Ferdinando D'Amico, Alessandra Zilli, Gionata Fiorino, Silvio Danese, Federica Furfaro

Summary: Endoscopy is essential for evaluating inflammatory bowel disease and monitoring colorectal cancer. Advances in virtual chromoendoscopy and artificial intelligence are reshaping the field, while tools like endocytoscopy and pCLE enhance inflammation and dysplasia assessment. The combination of pCLE and molecular labeling may lead to personalized medicine.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Review Medicine, General & Internal

Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future

Virginia Solitano, Alessandra Zilli, Gianluca Franchellucci, Mariangela Allocca, Gionata Fiorino, Federica Furfaro, Ferdinando D'Amico, Silvio Danese, Sameer Al Awadhi

Summary: Artificial intelligence (AI) is increasingly playing a crucial role in various medical fields, particularly in the detection and classification of gastrointestinal lesions during endoscopy. In the field of inflammatory bowel disease (IBD), AI has the potential to overcome human limitations and serve as a powerful tool for precision medicine decision-making. This review discusses the current state-of-the-art and identifies research gaps in the application of AI in endoscopy for IBD at the beginning of 2022.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Review Medicine, General & Internal

Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art

Edoardo Vespa, Ferdinando D'Amico, Mauro Sollai, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Arianna Dal Buono, Roberto Gabbiadini, Silvio Danese, Gionata Fiorino

Summary: Histological assessment is an important measure of disease activity in inflammatory bowel diseases. For ulcerative colitis, histological activity is associated with relapse rates, corticosteroid use, and long-term complications, making it a potential treatment target. Several histological scoring systems are available, but their use in Crohn's disease is limited by the discontinuous nature of lesions.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study

Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Inca, Marco Astegiano, Walter Fries, Monica Milla, Carolina Ciacci, Fernando Rizzello, Simone Saibeni, Rachele Ciccocioppo, Ambrogio Orlando, Fabrizio Bossa, Mariabeatrice Principi, Piero Vernia, Chiara Ricci, Maria L. Scribano, Giorgia Bodini, Dario Mazzucco, Gabrio Bassotti, Gabriele Riegler, Andrea Buda, Matteo Neri, Flavio Caprioli, Fabio Monica, Aldo Manca, Erica Villa, Gionata Fiorino, Michele Comberlato, Nicola Aronico, Cristina Della Corte, Roberta Caccaro, Paolo Gionchetti, Paolo Giuffrida, Paola Iovino, Marco Lenti, Caterina Mengoli, Lucienne Pellegrini, Alberto Pieraccini, Davide Ribaldone, Anna Testa, Cristina Ubezio, Anna Viola, Maurizio Vecchi, Catherine Klersy, Antonio Di Sabatino

Summary: The prevalence of anemia in Italian IBD patients is lower than previously reported, with the majority being caused by iron deficiency and leading to fatigue and decreased quality of life. However, a large proportion of patients with iron and/or vitamin deficiencies remain untreated.

INFLAMMATORY BOWEL DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience

Ferdinando D'Amico, Olga Tasopoulou, Gionata Fiorino, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Pierpaolo Sileri, Antonino Spinelli, Laurent Peyrin-Biroulet, Silvio Danese

Summary: This study aimed to investigate the impact of postoperative biological therapy on the incidence of endoscopic recurrence and long-term outcomes in Crohn's disease patients. The results showed that early treatment with biologics decreased the rates of endoscopic recurrence and hospitalization/surgery.

INFLAMMATORY BOWEL DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame

Cristina Bezzio, Gionata Fiorino, Davide G. Ribaldone, Alessandro Armuzzi, Simone Saibeni

Summary: This study investigated the impact of severe acute respiratory syndrome coronavirus 2 infection on inflammatory bowel disease course and found that therapy discontinuation is a risk factor for disease flare.

INFLAMMATORY BOWEL DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Re duce d humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study

Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Mariella Mannino, Giuseppe Rizzo, Ambrogio Orlando

Summary: The study investigated the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) treated with immunomodulatory or biological drugs. The majority of IBD patients showed seropositivity after COVID-19 vaccination, but the magnitude of the humoral response was significantly lower compared to healthy controls. These findings suggest that the lower response is mostly unrelated to the use of immune-modifying treatments.

DIGESTIVE AND LIVER DISEASE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation

Joana Torres, Maria Chaparro, Mette Julsgaard, Konstantinos Katsanos, Zuzana Zelinkova, Manasi Agrawal, Sandro Ardizzone, Marjo Campmans-Kuijpers, Gabriele Dragoni, Marc Ferrante, Gionata Fiorino, Emma Flanagan, Catarina Frias Gomes, Ailsa Hart, Charlotte Rose Hedin, Pascal Juillerat, Annemarie Mulders, Par Myrelid, Aoibhlinn O'Toole, Pauline Riviere, Michael Scharl, Christian Philipp Selinger, Elena Sonnenberg, Murat Toruner, Jantien Wieringa, C. Janneke Van der Woude

JOURNAL OF CROHNS & COLITIS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis

Paolo Angelo Cortesi, Gionata Fiorino, Laurent Peyrin-Biroulet, Lorenzo Giovanni Mantovani, Vipul Jairath, Kristine Paridaens, Fredrik L. Andersson, Silvio Danese

Summary: This study assessed the cost-effectiveness of a treat-to-target strategy based on clinical signs and faecal calprotectin levels in patients with mild-moderate ulcerative colitis. The results showed that this approach increased the time spent in clinical remission and reduced the number of relapses compared to a strategy based solely on symptoms. However, it was also associated with higher costs.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply

Paolo Angelo Cortesi, Gionata Fiorino, Lorenzo Giovanni Mantovani, Silvio Danese

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo

Luca Massimino, Orazio Palmieri, Amanda Facoetti, Davide Fuggetta, Salvatore Spano, Luigi Antonio Lamparelli, Silvia D'Alessio, Stefania Cagliani, Federica Furfaro, Ferdinando D'Amico, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Daniele Noviello, Anna Latiano, Fabrizio Bossa, Tiziana Latiano, Alessandra Pirola, Luca Mologni, Rocco Giovanni Piazza, Danilo Abbati, Francesco Perri, Chiara Bonini, Laurent Peyrin-Biroulet, Alberto Malesci, Vipul Jairath, Silvio Danese, Federica Ungaro

Summary: This study found that the virome-associated protein encoded by the hepatitis B virus (HBx) is detected in about 45% of patients with ulcerative colitis (UC) and is associated with UC progression. Experimental findings showed that HBx induces colonic inflammation and its silencing reverses the colitis phenotype. HBx acts as a transcriptional regulator in epithelial cells, leading to barrier leakage and altering mucosal immunity. This study provides a new perspective on targeted treatments for the virome composition of the gut microbiota.

GUT (2023)

添加到收藏夹

Review Medicine, General & Internal

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis

Sarah Bencardino, Ferdinando D'Amico, Ilaria Faggiani, Francesca Bernardi, Mariangela Allocca, Federica Furfaro, Tommaso Lorenzo Parigi, Alessandra Zilli, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese

Summary: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects patients' quality of life. There is a need for new drugs that target new pathways and minimize adverse events. Sphingosine-1-phosphate (S1P) receptor modulators have shown promise in reducing inflammation in UC by controlling the movement of immune cells. Several S1P receptor modulators, including ozanimod, etrasimod, and VTX002, have been developed and tested in UC. Oral administration, rapidity, and safety profile are the advantages of these drugs.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Review Medicine, General & Internal

The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease

Laura Cantoro, Rita Monterubbianesi, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Mariangela Allocca, Rocco Cosintino, Roberto Faggiani, Silvio Danese, Gionata Fiorino

Summary: Delayed diagnosis poses a challenge to managing inflammatory bowel disease (IBD), especially in Crohn's disease (CD). The Red Flags Index score, along with non-invasive biomarkers like fecal calprotectin, can effectively reduce diagnostic delay and aid in early treatment strategies for patients with IBD.

DIAGNOSTICS (2023)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

IMPLEMENTATION AND SHORT-TERM ADVERSE EVENTS OF ANTI-SARS-COV-2 VACCINES IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTERNATIONAL WEB-BASED SURVEY

Joana Reves, Barbara S. Abreu, Maria Chaparro, Javier P. Gisbert, Mariangela Allocca, Gionata Fiorino, Brigida Barberio, Fabiana Zingone, Anthea Pisani, David Cassar, Georgios Michalopoulos, Gerassimos J. Mantzaris, Katerina Mountaki, Ioannis E. Koutroubakis, Konstantinos Karmiris, Konstantinos Katsanos, Dana Duricova, Johan M. Burisch, Gorm Roager Madsen, Christian Maaser, Naila Arebi, Eleni Orfanoudaki, Vladimir Milivojevic, Anthony Buisson, Luisa Avedano, Salvatore Leone, Joana Torres, Pierre Ellul

GASTROENTEROLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.